Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hisamitsu Licenses for Percutaneous Pain Killer from Mundipharma
August 27, 2007
- R&D NEWS IN BRIEF
August 27, 2007
- Toho Pharm., Ohki, and Kokubu to Tie Up
August 27, 2007
- OPINION／Our Attitude Leads to Our Altitude
August 27, 2007
- Korosho Presents "Emergency Proposals" to Improve Business Practices
August 27, 2007
- Industry, Gov't, Academia to Jointly Develop New Medical Devices
August 27, 2007
- Discussion on Copyright on Literature Resumed
August 27, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 27, 2007
- BUSINESS NEWS IN BRIEF
August 27, 2007
- MOF Demands \220 Bil. Cut in Social Security Spending Again in FY2008
August 27, 2007
- Chuikyo to Show Road Map for Revisions of Medical Fees in April 2008
August 27, 2007
- SEMINAR
August 27, 2007
- Korosho Starts Studies for Mutual Acceptance of Clinical Data from Japan, Korea, China
August 27, 2007
- DSP to Independently Market Lurasidone in US
August 27, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2007
- JGPMA to Enhance Reliability of Generics: Mr Sawai
August 20, 2007
- Candidates Recommended by JMA, JPA Lose Seats in Upper House
August 20, 2007
- JMA Presents Strong Objection to the Use of Generics: Chuikyo
August 20, 2007
- LDP Must Review Its Medical Expenditure Curtailment Policy: JMA
August 20, 2007
- New NHI Pricing Systems Proposed by Industry Organizations
August 20, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…